Shares of Seres Therapeutics Inc. (NASDAQ:MCRB) saw an uptick in trading volume on Monday . 282,029 shares were traded during mid-day trading, a decline of 17% from the previous session’s volume of 340,944 shares.The stock last traded at $30.67 and had previously closed at $29.99.

Several research firms recently weighed in on MCRB. Zacks Investment Research upgraded shares of Seres Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, April 21st. FBR & Co reiterated a “buy” rating on shares of Seres Therapeutics in a report on Friday. Cowen and Company began coverage on shares of Seres Therapeutics in a report on Monday, June 6th. They issued an “outperform” rating on the stock. Finally, Canaccord Genuity reiterated a “buy” rating on shares of Seres Therapeutics in a report on Sunday, May 29th. One analyst has rated the stock with a sell rating, one has issued a hold rating and seven have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and an average price target of $43.86.

The firm’s market cap is $1.21 billion. The company’s 50 day moving average price is $30.35 and its 200 day moving average price is $28.08.

Seres Therapeutics (NASDAQ:MCRB) last issued its quarterly earnings data on Monday, May 16th. The company reported ($0.50) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.48) by $0.02. The business earned $2.71 million during the quarter, compared to the consensus estimate of $1.25 million. On average, equities analysts forecast that Seres Therapeutics Inc. will post ($1.81) earnings per share for the current year.

In other Seres Therapeutics news, CFO Eric D. Shaff sold 4,533 shares of the business’s stock in a transaction dated Thursday, June 30th. The stock was sold at an average price of $29.54, for a total transaction of $133,904.82. Following the transaction, the chief financial officer now owns 4,533 shares in the company, valued at $133,904.82. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CEO Roger Pomerantz sold 67,367 shares of the business’s stock in a transaction dated Tuesday, May 3rd. The stock was sold at an average price of $28.70, for a total value of $1,933,432.90. Following the transaction, the chief executive officer now owns 66,414 shares in the company, valued at approximately $1,906,081.80. The disclosure for this sale can be found here.

Several hedge funds and institutional investors recently modified their holdings of the company. Jennison Associates LLC boosted its position in shares of Seres Therapeutics by 1.9% in the fourth quarter. Jennison Associates LLC now owns 398,959 shares of the company’s stock worth $13,999,000 after buying an additional 7,259 shares in the last quarter. Morgan Stanley raised its stake in shares of Seres Therapeutics by 225.3% in the fourth quarter. Morgan Stanley now owns 33,758 shares of the company’s stock worth $1,185,000 after buying an additional 23,381 shares during the last quarter. Finally, ProShare Advisors LLC acquired a new stake in shares of Seres Therapeutics during the fourth quarter worth about $1,146,000.

Seres Therapeutics, Inc is a microbiome therapeutics platform company. The Company is engaged in developing a range of biological drugs, Ecobiotic microbiome therapeutics. It is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome in the human body.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.